Aprea Therapeutics, Inc. Common stock
APRE US03836J2015
💰
Capitalization
Small-cap
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
🔗
Website
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -39% | -90% | -37% | -34% | 9% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
📊
Transactions
16
🙍
Insiders
5
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Gilad Oren CEO |
1.80 USD |
2,497 Bought |
4,495 USD |
03/04/2025 | 03/04/2025 |
| Gilad Oren CEO |
1.87 USD |
3,003 Bought |
5,616 USD |
03/04/2025 | 03/04/2025 |
| Gilad Oren CEO |
3.92 USD |
500 Bought |
1,958 USD |
23/10/2024 | 23/10/2024 |
| Duey Marc O |
4.58 USD |
6,462 Sold |
29,583 USD |
18/10/2024 | 18/10/2024 |
| Duey Marc O |
4.39 USD |
30,000 Bought |
131,700 USD |
16/10/2024 | 16/10/2024 |
| Gilad Oren CEO |
2.90 USD |
250 Bought |
725 USD |
15/10/2024 | 15/10/2024 |
| Duey Marc O |
2.58 USD |
190 Bought |
490 USD |
14/10/2024 | 14/10/2024 |
| Gilad Oren CEO |
2.59 USD |
1,000 Bought |
2,590 USD |
10/10/2024 | 14/10/2024 |
| Seizinger Bernd R. O |
2.68 USD |
10,000 Bought |
26,800 USD |
11/10/2024 | 11/10/2024 |
| Hamill John P. VP |
2.46 USD |
50 Bought |
123 USD |
11/10/2024 | 11/10/2024 |